The first wealth is health.
– Ralph Waldo Emerson
Spotlight: Dr. Fernandez-Miranda
This month the PNA Spotlight focuses on Dr. Juan Carlos Fernandez-Miranda, a Professor of Neurosurgery and the Surgical Director of Brain Tumor, Skull Base and Pituitary Centers at Stanford University. Dr. Fernandez-Miranda did a neurosurgery residency at La Paz University Hospital in Madrid, Spain. He completed a fellowship in microsurgical neuroanatomy at the University of Florida. He did clinical training in cerebrovascular surgery at the University of Virginia, and in endoscopic endonasal and open skull base surgery at University of Pittsburgh Medical Center (UPMC). He joined the faculty at Stanford earlier this year. He was kind enough to answer some questions from the PNA. His answers are below:
What inspired you to choose your career path?
When I was a young kid, about 10-11 years old, I got sick with a skin rash and high fever; the family doctor visited our home, carefully examined me, and based on a number of clues, he determined I got a very rare bacterial infection known as scarlet fever; a few days of antibiotic medication and I was back to normal. I now realized that I was fascinated by the wisdom, expertise, and detective attitude of the physician, and this personal event was (I now know) key to my future decision to become a doctor.
Medical Corner: Can Prolactin Protect You?
This month the PNA Medical Corner spotlights an article co-authored by PNA member G. Edward Vates, a professor of neurosurgery at the University of Rochester. The study finds that a moderately high level of prolactin (but not excessively high level) seems to protect retinal function in patients with a tumor squeezing the optic chiasm.
Link: https://pubmed.ncbi.nlm.nih.gov/35921360/
Prolactin at moderately increased levels confers a neuroprotective effect in non-secreting pituitary macroadenomas.
Affiliations expand
• PMID: 35921360 PMCID: PMC9348739 DOI: 10.1371/journal.pone.0271690
Abstract
Magnolia
PATHFNDR
Investigational Studies to Evaluate the Safety and Efficacy of Paltusotine in Patients with Acromegaly
The PATHFNDR studies are recruiting patients to participate in clinical research for once-daily paltusotine for the treatment of acromegaly. If the studies are successful, paltusotine could be approved as a ONCE-DAILY, ORAL treatment option that gives patients an alternative to injections or twice-daily oral medications.
As a study participant, you could play an important role in advancing the options available for acromegaly treatment for yourself and many others living with this rare disease.
ABOUT THE STUDIES
The purpose of the PATHFNDR studies is to see if Crinetics Pharmaceutical's investigational medication, paltusotine, is safe and effective in patients with acromegaly.
PATHFNDR-1 is a randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine in
subjects with acromegaly treated with somatostatin receptor ligand (SRL) based treatment regimens. Clinicaltrials.gov
PATHFNDR-2 is a randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine in
subjects with non-pharmacologically treated acromegaly. Clinicaltrials.gov
1(855) 848-8486
Copyright © 2024 Pituitary Network Association All rights reserved.
Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.
Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email [email protected]
You are receiving this Newsletter because you have shown interest in receiving information about our activities.
If you do not want to receive any more emails from PNA, Unsubscribe.